LENZ Therapeutics Rings the Closing Bell

About This Event

LENZ Therapeutics (Nasdaq: LENZ), visits the Nasdaq MarketSite in Times Square. LENZ Therapeutics is a late-stage clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia.

In honor of the occasion, Eef Schimmelpennink, Chief Executive Officer, rings the Closing Bell.